Arrowpoint Investment Partners Singapore Pte. Ltd. Invests $2.94 Million in Natera, Inc. (NASDAQ:NTRA)

Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in Natera, Inc. (NASDAQ:NTRA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 18,578 shares of the medical research company's stock, valued at approximately $2,941,000. Natera makes up approximately 0.6% of Arrowpoint Investment Partners Singapore Pte. Ltd.'s holdings, making the stock its 12th biggest holding.

Several other large investors have also recently added to or reduced their stakes in NTRA. LRI Investments LLC bought a new stake in Natera during the fourth quarter worth approximately $29,000. Blue Trust Inc. increased its position in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after purchasing an additional 97 shares during the period. EverSource Wealth Advisors LLC raised its stake in shares of Natera by 372.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after buying an additional 261 shares in the last quarter. Principal Securities Inc. lifted its holdings in shares of Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after buying an additional 59 shares during the period. Finally, Steward Partners Investment Advisory LLC lifted its holdings in shares of Natera by 1,328.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after buying an additional 332 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Stock Performance

Shares of Natera stock opened at $154.53 on Wednesday. The stock has a market cap of $21.10 billion, a PE ratio of -87.80 and a beta of 1.79. Natera, Inc. has a 12 month low of $92.14 and a 12 month high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The business has a fifty day simple moving average of $149.13 and a 200-day simple moving average of $157.15.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.09. The company had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business's revenue for the quarter was up 36.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.56) EPS. On average, sell-side analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Canaccord Genuity Group reaffirmed a "buy" rating and set a $180.00 target price on shares of Natera in a report on Wednesday, February 26th. Morgan Stanley raised their price objective on shares of Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. StockNews.com cut shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday. Robert W. Baird boosted their target price on shares of Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Finally, UBS Group increased their target price on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research note on Friday, May 9th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $182.12.

Insider Buying and Selling at Natera

In other news, insider Solomon Moshkevich sold 6,000 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $143.29, for a total transaction of $859,740.00. Following the completion of the sale, the insider now directly owns 143,768 shares of the company's stock, valued at $20,600,516.72. This trade represents a 4.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Steven Leonard Chapman sold 87,272 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $143.40, for a total value of $12,514,804.80. Following the completion of the sale, the chief executive officer now directly owns 203,354 shares of the company's stock, valued at approximately $29,160,963.60. The trade was a 30.03% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 152,436 shares of company stock worth $22,019,079. 7.60% of the stock is currently owned by company insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.